These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 25677024)

  • 1. Research gaps in pancreatic cancer research and comparative effectiveness research methodologies.
    In H; Posner MC
    Cancer Treat Res; 2015; 164():165-94. PubMed ID: 25677024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma.
    Stojadinovic A; Brooks A; Hoos A; Jaques DP; Conlon KC; Brennan MF
    J Am Coll Surg; 2003 Jun; 196(6):954-64. PubMed ID: 12788434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide does not prevent postoperative pancreatic fistula or mortality following Pancreaticoduodenectomy.
    Barnett SP; Hodul PJ; Creech S; Pickleman J; Arahna GV
    Am Surg; 2004 Mar; 70(3):222-6; discussion 227. PubMed ID: 15055845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide prophylaxis is not beneficial for biochemical activity and clinical severity of postoperative pancreatic fistula after pancreatic surgery.
    Droeser RA; Jeanmonod P; Schuld J; Moussavian MR; Schilling MK; Kollmar O
    Dig Surg; 2012; 29(6):484-91. PubMed ID: 23392293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on the article by Droeser et al.: 'Octreotide prophylaxis is not beneficial for biochemical activity and clinical severity of postoperative pancreatic fistula after pancreatic surgery'.
    Büchler MW
    Dig Surg; 2013; 30(4-6):328-9. PubMed ID: 24051517
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pancreaticoduodenectomy in the era of evidence based medicine].
    Sastre B; Ouassi M; Pirro N; Cosentino B; Sielezneff I
    Ann Chir; 2005 Jun; 130(5):295-302. PubMed ID: 15935785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic neoplasm in 2011: an update.
    Saif MW
    JOP; 2011 Jul; 12(4):316-21. PubMed ID: 21737886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness issues in lung cancer.
    Varghese TK
    Cancer Treat Res; 2015; 164():101-19. PubMed ID: 25677021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of pancreatic fistula following pancreaticoduodenectomy for periampullary cancer.
    Popiela T; Kedra B; Sierzega M; Gurda A
    Hepatogastroenterology; 2004; 51(59):1484-8. PubMed ID: 15362783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward zero pancreatic fistula after pancreaticoduodenectomy with pancreaticogastrostomy.
    Rosso E; Bachellier P; Oussoultzoglou E; Scurtu R; Meyer N; Nakano H; Verasay G; Jaeck D
    Am J Surg; 2006 Jun; 191(6):726-32; discussion 733-4. PubMed ID: 16720139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Surgical standard therapy for cancer of the pancreas].
    Friess H; Kleeff J; Fischer L; Müller M; Büchler MW
    Chirurg; 2003 Mar; 74(3):183-90. PubMed ID: 12647074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the surgical management of pancreatic cancer.
    Spanknebel K; Conlon KC
    Cancer J; 2001; 7(4):312-23. PubMed ID: 11561607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of prophylactic long-acting octreotide in high-risk patients undergoing pancreaticoduodenectomy.
    Graham JA; Johnson LB; Haddad N; Al-Kawas F; Carroll J; Jha R; Wong J; Maglaris D; Mertens S; Fishbein T
    Am J Surg; 2011 Apr; 201(4):481-5. PubMed ID: 21421102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational research. New findings and potential future applications in pancreatic adenocarcinoma.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Mar; 13(2):177-9. PubMed ID: 22406595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
    Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
    J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective administration of prophylactic octreotide during pancreaticoduodenectomy: a clinical and cost-benefit analysis in low- and high-risk glands.
    Vanounou T; Pratt WB; Callery MP; Vollmer CM
    J Am Coll Surg; 2007 Oct; 205(4):546-57. PubMed ID: 17903728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measures to prevent pancreatic fistula after pancreatoduodenectomy: a comprehensive review.
    Lai EC; Lau SH; Lau WY
    Arch Surg; 2009 Nov; 144(11):1074-80. PubMed ID: 19917946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safe management of the pancreatic remnant with prolamine duct occlusion after extended pancreaticoduodenectomy.
    Shimada K; Sano T; Sakamoto Y; Kosuge T
    Hepatogastroenterology; 2005; 52(66):1874-7. PubMed ID: 16334797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of internal stenting of pancreatojejunostomy on the pancreatic fistula rate after pancreaticoduodenectomy.
    Xu XF; Li JA; Lou WH
    Am Surg; 2014 Feb; 80(2):215-6. PubMed ID: 24480229
    [No Abstract]   [Full Text] [Related]  

  • 20. Pancreatic cancer: updates on translational research and future applications.
    Sarris EG; Syrigos KN; Saif MW
    JOP; 2013 Mar; 14(2):145-8. PubMed ID: 23474558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.